TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31588660
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of clinical and mRNA biomarkers
Study: 31590634
Drug: Self-report questionnaires
Normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-report questionnaires administered to measure cognitive complaints, fatigue, anxiety, depressive symptoms
Study: 31591636
Drug: Endocrine Therapy
Normalized name: ENDOCRINE THERAPY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endocrine Therapy (ET) in postmenopausal patients
Study: 31591636
Drug: Chemotherapy (CT)
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (CT) in premenopausal patients
Study: 31592772
Drug: Home-based aerobic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home-based aerobic and strengthening exercises during preoperative chemotherapy or chemoradiation
Study: 31593308
Drug: Metformin (2000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (2000 mg/day for a minimum of 9 days, mean 13.6 days)
Study: 31594647
Drug: ACHIM (anaerobic
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACHIM (anaerobic cultivated human intestinal microbiota) administered via upper gastrointestinal route using endoscopy for 10 days
Study: 31594667
Drug: Elbasvir/grazoprevir (EBR/GZR)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elbasvir/grazoprevir (EBR/GZR) treatment
Study: 31595258
Drug: Nursing care
Normalized name: Petrolatum Topical application Ointment [NURSING CARE PROTECTIVE]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nursing care intervention centered on basic self-care including twice daily walking training, privileging pre-established trips to the toilet by walking, and all daytime meals seated, off the bed.
Study: 31595259
Drug: Intervention program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention program comprising 3 weekly classes of physical exercise (45/50 min each) delivered by trained teachers after teachers' training by researchers.
Study: 31595670
Drug: Prophylaxis treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylaxis treatment in hemophilia
Study: 31595793
Drug: Dosage-controlled cannabis
Normalized name: Medical Cannabis
DrugBank: Medical Cannabis (DB14009)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosage-controlled cannabis capsules; specific dosage and duration not available
Study: 31595982
Drug: Calcimimetic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcimimetic treatment (30-60 mg daily for 4 weeks)
Study: 31597157
Drug: Less intensive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Less intensive chemotherapy with autotransplant
Study: 31597157
Drug: White blood
Normalized name: Human white blood cell product
Approvals — FDA: no, EMA: no, PMDA: no
Description: White blood cells ≥100 × 10^9/L at study entry
Study: 31598047
Drug: Melatonin 6
Normalized name: melatonin 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin 6 mg sublingually as premedication
Study: 31598139
Drug: Fingolimod 0.5
Normalized name: fingolimod 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fingolimod 0.5 mg orally once daily
Study: 31598646
Drug: Fluzone High-Dose
Normalized name: Fluzone High-Dose
DrugBank: Influenza A virus A/Kansas/14/2017 X-327 (H3N2) antigen (formaldehyde inactivated) (DB15516)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluzone High-Dose (egg-based)
Study: 31599928
Drug: Sodium nitrate
Normalized name: Sodium Nitrate
DrugBank: Sodium nitrate (DB15952)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium nitrate (1 g/L in drinking water for 7 days)
Study: 31599928
Drug: Sodium nitrite
Normalized name: Sodium Nitrite
DrugBank: Nitrous acid (DB09112)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium nitrite (10 μmol/min infusion for 30 minutes)
Study: 31600167
Drug: Low-dose capecitabine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose capecitabine (150 mg bid)
Study: 31600167
Drug: Low-dose capecitabine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose capecitabine (300 mg bid)
Study: 31600167
Drug: Low-dose capecitabine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose capecitabine (450 mg bid)
Study: 31601588
Drug: Oral glucose
Normalized name: glucose Oral Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral glucose tolerance test and insulin test at 24-28 weeks' gestation
Study: 31601596
Drug: Oral glyburide
Normalized name: Glyburide
DrugBank: Glyburide (DB01016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral glyburide administered within 8 hours of injury
Study: 31601596
Drug: Oral glyburide
Normalized name: Glyburide
DrugBank: Glyburide (DB01016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral glyburide
Study: 31602320
Drug: FoundationACT™ ctDNA
Approvals — FDA: no, EMA: no, PMDA: no
Description: FoundationACT™ ctDNA assay (Foundation Medicine, Cambridge, MA, USA)
Study: 31602518
Drug: Open abdomen
Normalized name: BOTTLE OPENER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open abdomen treatment in obese patients
Study: 31604419
Drug: Propofol induction
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol induction dose based on total body weight (TBW) scaled by phase angle value
Study: 31604419
Drug: Guiding propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Guiding propofol induction dose according to baseline frailty score
Study: 31604781
Drug: Blood pressure,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blood pressure, pulse wave velocity, and augmentation index measurement on two consecutive days.
Study: 31605278
Drug: Standard split
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard split dose of 4 l polyethylene glycol for bowel preparation
Study: 31605278
Drug: Rectal pain
Normalized name: Dermoplast Pain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal pain score during defecation < 2
Study: 31605516
Drug: Daily tips
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily tips and daily surveys from the Pocket Helper 2.0 app
Study: 31606970
Drug: Autologous cultured
Normalized name: Autologous cultured fibroblasts
DrugBank: Azficel-T (DB11051)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous cultured fibroblasts, 3 injections administered at 4-6 week intervals.
Study: 31607268
Drug: Infliximab (IFX)
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Infliximab (IFX) 5 mg/kg at Weeks 0, 2, and 6, with additional doses at Weeks 14 and 22 for CAI-based responders
Study: 31612225
Drug: Combination antiretroviral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination antiretroviral therapy (cART) initiated irrespective of CD4 cell count, with a median delay in initiation decreasing from 9.07 months in 2007 to 0.77 months in 2017.
Study: 31613328
Drug: Investigational norovirus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigational norovirus vaccine
Study: 31613706
Drug: Oatmeal consumption
Normalized name: OATMEAL
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oatmeal consumption (2 servings of instant oatmeal daily for 2 weeks)
Study: 31615432
Drug: Intact parathyroid
Normalized name: Intact parathyroid hormone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intact parathyroid hormone (iPTH) levels
Study: 31615556
Drug: Floseal® treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Floseal® treatment
Study: 31617211
Drug: Thrombocytosis (platelet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombocytosis (platelet count > 500 × 10^9/L)
Study: 31617269
Drug: Tabalumab (NTC00882999)
Normalized name: Tabalumab
DrugBank: Tabalumab (DB11657)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tabalumab (NTC00882999) - a BAFF inhibitor
Study: 31617269
Drug: Atacicept (NCT00642902)
Normalized name: Atacicept
DrugBank: Atacicept (DB06399)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atacicept (NCT00642902) - an APRIL and BAFF inhibitor
Study: 31618421
Drug: Hourly mixed
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hourly mixed meals providing variable protein (0.20-3.00 g·kg-1·d-1) as crystalline amino acids modeled after egg protein
Study: 31618746
Drug: Three consecutive
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three consecutive negative values (≤0.3 (ng/mL)2/1,000)
Study: 31618746
Drug: Emerging or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emerging or persistent strongly positive results (>2.0 (ng/mL)2/1,000)
Study: 31618746
Drug: Test results
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test results between 0.3 and 2.0 (ng/mL)2/1,000
Study: 31618804
Drug: Subcutaneous N8-GP
Normalized name: N8-GP
DrugBank: Turoctocog alfa pegol (DB14738)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Subcutaneous N8-GP (12.5, 25, 50, or 100 IU/kg single dose in part A; 2000 IU for patients <60 kg and 4000 IU for patients ≥60 kg daily for 3 months in part B)
Study: 31618804
Drug: Subcutaneous N8-GP
Normalized name: N8-GP
DrugBank: Turoctocog alfa pegol (DB14738)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Subcutaneous N8-GP
Study: 31619290
Drug: Rituximab-maintenance therapy
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab-maintenance therapy (375 mg/m2), 2 years duration after R-CVP treatment
Study: 31619290
Drug: Rituximab-maintenance therapy
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab-maintenance therapy
Study: 31619706
Drug: Carfilzomib-lenalidomide-dexamethasone (KRd)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carfilzomib-lenalidomide-dexamethasone (KRd) therapy
Study: 31620073
Drug: Aerobic training,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aerobic training, details on dosage and duration not specified
Study: 31620672
Drug: Legume supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Legume supplement providing 8.2 g/d of protein
Study: 31620836
Drug: Appropriate antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Appropriate antibiotic treatment
Study: 31620836
Drug: Inappropriate antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inappropriate antibiotic treatment
Study: 31621458
Drug: Immune globulin
Normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immune globulin subcutaneous, human - klhw 20%
Study: 31621477
Drug: SUPERA™ stent
Approvals — FDA: no, EMA: no, PMDA: no
Description: SUPERA™ stent and drug-coated balloon (Passeo-18 Lux™)
Study: 31623843
Drug: Ultra-processed food
Normalized name: Allogeneic processed thymus tissue
DrugBank: Allogeneic processed thymus tissue (DB16736)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultra-processed food consumption (average 385 g/d, 24.4% of total energy intake)
Study: 31626037
Drug: Various treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various treatment strategies (19 different strategies applied)
Study: 31626649
Drug: Liquorice ingestion
Normalized name: Liquorice
DrugBank: Licorice (DB10675)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liquorice ingestion (290-370 mg/d glycyrrhizin)
Study: 31627014
Drug: Semantic naming
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Semantic naming treatment for 12 weeks
Study: 31627014
Drug: Patients with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with chronic aphasia pre-treatment
Study: 31627014
Drug: Patients with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with chronic aphasia post-treatment
Study: 31628118
Drug: Fast decline
Normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fast decline in eGFR (lowest quartile of eGFR slope -4.1 ml/min per 1.73 m²)
Study: 31628118
Drug: Baseline eGFR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline eGFR (median 73 ml/min per 1.73 m²)
Study: 31628130
Drug: Seven biomarkers
Normalized name: Sevenfact
DrugBank: Coagulation factor VIIa Recombinant Human (DB00036)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Seven biomarkers (NR2, NR2 antibodies, PARK7, NDKA, UFD1, B-FABP, H-FABP)
Study: 31628667
Drug: Intradermal injection
Normalized name: Dryvax Intradermal Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal injection of mixed methylene blue compound
Study: 31628986
Drug: Laparoscopic sentinel
Normalized name: Sentinel Spectrum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laparoscopic sentinel lymph node technique using 200 microliters of saline solution containing 37 MBq of technetium-99m nanocolloid followed by 0.5 mL of indocyanine green (ICG) injected subperitoneally.
Study: 31628986
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of technetium-99m nanocolloid and indocyanine green (ICG) for sentinel lymph node identification
Study: 31632154
Drug: Extended-release guaifenesin
Normalized name: guaifenesin Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release guaifenesin 1200 mg (Mucinex)
Study: 31632387
Drug: Agonistic autoantibodies
Approvals — FDA: no, EMA: no, PMDA: no
Description: Agonistic autoantibodies (agAAb) activating the β2-adrenergic receptor
Study: 31634407
Drug: Phrenic nerve
Normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phrenic nerve stimulation (PNS) therapy
Study: 31636050
Drug: Patients with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with lymphedema undergoing complete decongestive therapy
Study: 31636342
Drug: Rituximab; specific
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rituximab; specific dosage and duration not available
Study: 31637669
Drug: Olaparib (tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olaparib (tablet 100 mg bid days 3-12) combined with carboplatin (AUC 4) and paclitaxel (175 mg/m2)
Study: 31637669
Drug: Olaparib (capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olaparib (capsule and tablet formulations) using intermittent schedules (2 to 10 days of a 21-day cycle) combined with carboplatin/paclitaxel
Study: 31638652
Drug: Rivaroxaban 15
Normalized name: rivaroxaban 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban 15 mg
Study: 31639039
Drug: Avelumab (MSB0010718C)
Normalized name: Avelumab
DrugBank: Avelumab (DB11945)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Avelumab (MSB0010718C) at doses of 10 mg/kg to 20 mg/kg every 2 weeks until disease progression or intolerable side effects
Study: 31639692
Drug: Mutant 4D4
Normalized name: STREPTOCOCCUS MUTANS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mutant 4D4 (L3-2) antibody-assisted assay
Study: 31640565
Drug: Postoperative patient-controlled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative patient-controlled intravenous analgesia (PCIA) with 0.2 mg/kg hydromorphone and 4 mg/kg flurbiprofen; pump programmed as 2.0 mL/h background infusion with a loading dose of 1 mL and a lockout period of 15 min
Study: 31640565
Drug: Postoperative patient-controlled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative patient-controlled intravenous analgesia (PCIA)
Study: 31640741
Drug: Toothpaste containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Toothpaste containing 0.454% w/w stannous fluoride (1100 ppm fluoride), used twice daily for 24 weeks
Study: 31641633
Drug: Saxagliptin as
Normalized name: Saxagliptin
DrugBank: Saxagliptin (DB06335)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saxagliptin as add-on to metformin
Study: 31644328
Drug: MRD-based treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: MRD-based treatment stratification after induction treatment
Study: 31644328
Drug: Intensified treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensified treatment directly after induction for very poor responders
Study: 31644380
Drug: Urban Zen
Normalized name: Geum urbanum root extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urban Zen Integrative Therapy
Study: 31647026
Drug: Atezolizumab monotherapy
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Atezolizumab monotherapy for 1 year
Study: 31647026
Drug: Experimental vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental vaccine
Study: 31648294
Drug: CD19-directed chimeric
Normalized name: DIRECT BLUE 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: CD19-directed chimeric antigen receptor-modified T (CAR-T) cells, 2 × 10^6 cells per kilogram after lymphodepletion with cyclophosphamide and fludarabine
Study: 31648999
Drug: Osimertinib at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Osimertinib at the dose of 80 mg/d
Study: 31649017
Drug: Household contacts
Approvals — FDA: no, EMA: no, PMDA: no
Description: Household contacts exposed to drug sensitive tuberculosis
Study: 31650066
Drug: TetMYB vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TetMYB vaccine
Study: 31650066
Drug: TetMYB vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TetMYB vaccine and Anti-PD-1 antibody
Study: 31650077
Drug: Innovative combination
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Innovative combination intervention to improve access to pediatric cancer services and treatment adherence
Study: 31650176
Drug: High-dose cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose cyclophosphamide (HD-Cy) (3 g/m2)
Study: 31650176
Drug: Low-dose cyclophosphamide
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose cyclophosphamide (LD-Cy) (≤1.5 g/m2)
Study: 31650176
Drug: CD19-specific CAR
Normalized name: CAR.CD19-Redirected T cells
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CD19-specific CAR T-cell therapy
Study: 31650176
Drug: Dose intensity
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dose intensity of conditioning chemotherapy and minimal pretreatment disease burden
Study: 31650393
Drug: Age, diabetes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Age, diabetes duration, BMI, HbA1c, use of metformin, sulfonylurea derivatives, and DPP4 inhibitors
Study: 31651278
Drug: Simulated interventions
Normalized name: bisacodyl
DrugBank: Bisacodyl (DB09020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simulated interventions (e.g., iron fortification)
Study: 31651359
Drug: Avelumab 10
Normalized name: Avelumab
DrugBank: Avelumab (DB11945)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Avelumab 10 mg/kg intravenous infusion every 2 weeks (1 L subgroup)
Study: 31651359
Drug: Avelumab 10
Normalized name: Avelumab
DrugBank: Avelumab (DB11945)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Avelumab 10 mg/kg intravenous infusion every 2 weeks (2 L subgroup)
Study: 31651364
Drug: Standardized oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardized oral care bundle (oral assessment, tooth brushing, moisturization, and secretion removal)
Study: 31651364
Drug: Oral chlorhexidine
Normalized name: chlorhexidine Oral Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral chlorhexidine
Study: 31651951
Drug: Oral anticoagulant
Normalized name: CPDA-1 Anticoagulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral anticoagulant (OAC) use
Study: 31651951
Drug: Non-vitamin K
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-vitamin K antagonist oral anticoagulants (NOACs) use
Study: 31651951
Drug: Antiplatelet monotherapy
Normalized name: simethicone
DrugBank: Simethicone (DB09512)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiplatelet monotherapy
Study: 31652009
Drug: Oral iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral iron supplementation starting at 65 mg daily, titrated based on fasting serum iron concentration.
Study: 31652392
Drug: Posttransplant DAA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Posttransplant DAA therapy for viremic patients
Study: 31652997
Drug: RC28-E (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: RC28-E (5 mg/kg, 15 mg/kg, and 50 mg/kg, ip. Tiw × 9)
Study: 31652997
Drug: Mono-target antagonist
Normalized name: tiotropium bromide mono
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mono-target antagonist treatment (VEGF or FGF blocking)
Study: 31654285
Drug: Everolimus 5
Normalized name: everolimus 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Everolimus 5 mg PO daily and panobinostat 10 mg PO 3 times weekly (weeks 1 and 2) given in 21-day cycles
Study: 31654285
Drug: Everolimus/panobinostat therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Everolimus/panobinostat therapy
Study: 31655936
Drug: telotristat ethyl
Normalized name: Telotristat ethyl
DrugBank: Telotristat ethyl (DB12095)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: telotristat ethyl treatment
Study: 31657648
Drug: Fibroblast Growth
Normalized name: Fibroblast growth factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fibroblast Growth Factor Receptor Inhibitors
Study: 31659739
Drug: Anticoagulation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticoagulation therapy (AT)
Study: 31660391
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D supplementation (maintained serum 25(OH)D >30 ng/mL)
Study: 31660640
Drug: Tofacitinib de-escalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tofacitinib de-escalation (from 10 mg b.d. to 5 mg b.d.)
Study: 31660640
Drug: Tofacitinib escalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tofacitinib escalation (from 5 mg b.d. to 10 mg b.d.)
Study: 31660992
Drug: Curative surgery
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Curative surgery for rectal adenocarcinoma
Study: 31661530
Drug: Skhokho intervention,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Skhokho intervention, details on dosage and duration not available
Study: 31662377
Drug: MD Anderson
Normalized name: miconazole nitrate Topical Solution [Nail MD]
Approvals — FDA: no, EMA: no, PMDA: no
Description: MD Anderson Symptom Inventory-Lung Cancer Module (MDASI-LC) for symptom data collection preoperatively, daily postoperatively during in-hospital stay, and weekly after discharge until 4 weeks or start of postoperative oncological therapy.